TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16173134
Drug: Curcuma xanthorriza
Normalized name: Curcuma xanthorrhiza oil
DrugBank: Curcuma xanthorrhiza oil (DB11265)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuma xanthorriza 60 mg daily (curcuma group)
Study: 11868058
Drug: tranilast (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: tranilast (600 mg/day for 3 months)
Study: 8882259
Drug: ketorolac 10
Normalized name: ketorolac 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketorolac 10 mg
Study: 8882259
Drug: lignocaine 10
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: lignocaine 10 mg
Study: 1948092
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg SSHA (administered daily for 11 days, with 40 mg SC administered three times every 90 min on the first day)
Study: 1948092
Drug: 10, 20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10, 20, 40, and 70 mg SSHA (dose-dependent effect tested)
Study: 24994842
Drug: Standard and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard and new antiepileptic drugs (monotherapy)
Study: 24994842
Drug: First treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: First treatment failure
Study: 22813445
Drug: Buspirone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (10 mg, 3 times daily for 4 weeks)
Study: 21122491
Drug: 4g enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4g enema administered daily (Group A, 15 pts)
Study: 21122491
Drug: 4g enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4g enema administered every 2 days (Group B, 15 pts)
Study: 21122491
Drug: 4g enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4g enema administered every 3 days (Group C, 15 pts)
Study: 21122491
Drug: Oral Mesalazine
Normalized name: mesalamine Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Mesalazine treatment alone (OT)
Study: 16127749
Drug: Capsaicin (1-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin (1-8 microg/mL, 100 mL)
Study: 16127749
Drug: Capsaicin (3x400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin (3x400 microg i.g. for two weeks)
Study: 11464575
Drug: rhFSH +
Normalized name: rhTSH
DrugBank: Thyrotropin alfa (DB00024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhFSH + rhLH (group L)
Study: 11464575
Drug: Subgroup of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgroup of group L (previous ART cycle with FSH only)
Study: 5923
Drug: IV lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV lorazepam (4 mg) plus IM meperidine (50 mg)
Study: 5923
Drug: IV placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV placebo plus IM meperidine (50 mg)
Study: 6987032
Drug: Phenformin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenformin (50 mg)
Study: 30208866
Drug: Durvalumab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (5 mg)
Study: 30208866
Drug: Durvalumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (10 mg)
Study: 30208866
Drug: Durvalumab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (20 mg)
Study: 24810796
Drug: Atropine administration
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine administration without prior oxygen
Study: 18060379
Drug: Atropine administration
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine administration
Study: 21945866
Drug: lipid emulsion,
Approvals — FDA: no, EMA: no, PMDA: no
Description: lipid emulsion, LE (15 g Fabuless, containing 4.2g lipid, 0.2 MJ)+water
Study: 21945866
Drug: lipid control,
Approvals — FDA: no, EMA: no, PMDA: no
Description: lipid control, LC (15 g non‐emulsified lipid/water, containing 4.2g lipid, 0.2 MJ)+water
Study: 20414715
Drug: Modular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modular treatment in clinic settings
Study: 20414715
Drug: Modular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modular treatment in community settings
Study: 11943438
Drug: Antiretroviral drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral drug A
Study: 11943438
Drug: Antiretroviral drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral drug B
Study: 8602629
Drug: GM‐CSF 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM‐CSF 250 microg/m2 subcutaneously every 12 hr after each course of DICEP until recovery of ANC of 1.5 x 10(9)/L
Study: 8602629
Drug: Placebo subcutaneously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneously every 12 hr after each course of DICEP until recovery of ANC of 1.5 x 10(9)/L
Study: 1761663
Drug: Delayed administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed administration of human chorionic gonadotrophin (HCG) by 24 hours in 96 patients.
Study: 1761663
Drug: Standard administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard administration of human chorionic gonadotrophin (HCG) in 47 patients when the three largest follicles were >= 17 mm.
Study: 7080505
Drug: Hexoprenaline (beta‐2‐selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexoprenaline (beta‐2‐selective bronchodilator) in paediatric syrup form, dosage not specified, duration not specified
Study: 31823222
Drug: Dupilumab 200
Normalized name: dupilumab 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 200 or 300 mg every 2 weeks (q2w)
Study: 25028506
Drug: Transdermal 4-hydroxytamoxifen
Normalized name: 4-hydroxytamoxifen
DrugBank: Afimoxifene (DB04468)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 4-hydroxytamoxifen gel (4-OHT) 4 mg/day
Study: 25028506
Drug: Oral tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tamoxifen (oral-T) 20 mg/day
Study: 25028506
Drug: Transdermal 4-hydroxytamoxifen
Normalized name: 4-hydroxytamoxifen
DrugBank: Afimoxifene (DB04468)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 4-hydroxytamoxifen gel (4-OHT)
Study: 25028506
Drug: Oral tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tamoxifen (oral-T)
Study: 22656335
Drug: Zinc (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (10 mg orally daily)
Study: 12817747
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) with cyclic estrogen and progestogen (norethisterone acetate) for 2 years
Study: 2188408
Drug: Terbutaline via
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline via freon spray (aerosol)
Study: 27476110
Drug: Affect Regulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Affect Regulation Treatment to Enhance Methamphetamine Intervention Success (ARTEMIS)
Study: 22415569
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg rosiglitazone daily for 12 weeks
Study: 7577408
Drug: rhGH 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH 0.05 mg/kg per day subcutaneously
Study: 2289216
Drug: Enalapril (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (up to 40 mg daily)
Study: 2289216
Drug: Sustained-release diltiazem
Normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release diltiazem (360 mg daily)
Study: 26038356
Drug: Ibandronate (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate (6 mg intravenous or 50 mg oral)
Study: 21790680
Drug: Topical beclomethasone
Normalized name: beclomethasone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical beclomethasone dipropionate (BDP) 3mg enema during radiotherapy and 2x3mg suppositories for 4 weeks
Study: 21790680
Drug: Topical beclomethasone
Normalized name: beclomethasone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical beclomethasone dipropionate (BDP)
Study: 20175432
Drug: 6.4% CHO‐E
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.4% CHO‐E solution
Study: 10198297
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution (PLA)
Study: 15024373
Drug: Chlorhexidine gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gluconate (spray or swab)
Study: 2499524
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg ibuprofen-lysinsalt
Study: 30947740
Drug: Humidified high-flow
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humidified high-flow oxygenation via nasal cannula at 60 L/min
Study: 30947740
Drug: Non-rebreather mask
Normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-rebreather mask and standard nasal cannula at an oxygen flow rate of 15 L/min
Study: 25667281
Drug: Image-Guided Radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Image-Guided Radiation Therapy (IGRT)
Study: 18266537
Drug: Non-aggression-focused behavioral
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-aggression-focused behavioral couple therapy
Study: 16365124
Drug: Immediate weight-bearing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate weight-bearing mobilisation after conservative treatment
Study: 14651538
Drug: Intravenous ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous ibuprofen lysine 10 mg/kg, followed by 5 mg/kg after 24 and 48 h (n = 32)
Study: 14651538
Drug: Intravenous indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous indomethacin 0.2 mg/kg every 12 h for three doses (n = 31)
Study: 6356902
Drug: Labetalol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (100 mg twice a day)
Study: 6356902
Drug: Labetalol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (400 mg twice a day, maximum dose)
Study: 8680787
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of recombinant tissue plasminogen activator (tPA) compounded in 1% hyaluronate acid (HA) at doses of 0.25, 0.5, and 1.0 mg/ml for 4 weeks
Study: 28721886
Drug: Yoga intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga intervention (twice-weekly classes during RT)
Study: 16306923
Drug: Mediterranean diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean diet group (MG; n=48)
Study: 8087579
Drug: Standardized therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized therapy via computerized protocols
Study: 3815140
Drug: Cefazolin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (1 g intravenous injections, four doses over 12 hours)
Study: 3815140
Drug: Cefamandole (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole (750 mg intravenous injections, four doses)
Study: 15388432
Drug: Both antibiotics
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both antibiotics
Study: 26027135
Drug: Supplementing Qi
Normalized name: San Qi Root
DrugBank: Panax notoginseng root (DB14304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementing Qi and activating blood circulation herbs (60 mL per time, 3 times a day for 14 days)
Study: 10435606
Drug: Nalmefene (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene (20 mg/d and 80 mg/d)
Study: 7772078
Drug: Beta-carotene supplementation
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene supplementation (50-100 mg on alternate days for 3 weeks after a loading dose of 100 mg/day for 1 week)
Study: 729618
Drug: Tiamenidine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiamenidine 1.0 mg
Study: 30995329
Drug: Midazolam with
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam with magnesium (2 g bolus at 30 minutes, 16 mg/24-hour magnesium infusion)
Study: 30995329
Drug: Midazolam (0.03-0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.03-0.3 mg/kg bolus loading dose + 0.03-0.2 mg/kg/hour infusion)
Study: 19727982
Drug: BPD-LL with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPD-LL with high-calcium diet, 200 IU of vitamin D, and 100 mg elemental calcium daily
Study: 19727982
Drug: BPD-LL with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPD-LL with high-calcium diet, 200 IU of vitamin D, 100 mg elemental calcium daily, and an extra 2 g of calcium
Study: 11176084
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl at a target plasma concentration of 2.5 ng/ml
Study: 11176084
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia using ropivacaine in combination with 2 microg/ml fentanyl
Study: 9037222
Drug: Cortisol (perioperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol (perioperative injections)
Study: 9037222
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (perioperative injections)
Study: 22866937
Drug: Oat group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat group (100 grams of instant oat cereal daily)
Study: 22866937
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (100 grams of wheat flour-based noodles daily)
Study: 21803569
Drug: Everolimus 10mg
Normalized name: EVEROLIMUS 10MG TAB
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus 10mg once daily
Study: 26051564
Drug: Classical homeopathic
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classical homeopathic adjunctive therapy
Study: 19349312
Drug: Corticotropin-releasing hormone
Normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticotropin-releasing hormone (CRH) 1 microg/kg intravenously
Study: 16917445
Drug: Creatine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine administration (0.4 gr/kg daily for 6 months)
Study: 9143434
Drug: Tacrine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrine treatment in patients with WMLA
Study: 9143434
Drug: Tacrine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrine treatment in patients without WMLA
Study: 7968872
Drug: Nifedipine or
Normalized name: nifedipine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine or nitrendipine (3 to 6 month treatment)
Study: 3609121
Drug: Trimethoprim suspension
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trimethoprim suspension 3 mg/kg (fasting)
Study: 3609121
Drug: Trimethoprim suspension
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trimethoprim suspension 3 mg/kg (with food)
Study: 3609121
Drug: Trimethoprim suspension
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trimethoprim suspension 3 mg/kg (with food and guar)
Study: 26582972
Drug: A‐GPC (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: A‐GPC (600 mg per day)
Study: 18495508
Drug: Alendronate 70mg
Normalized name: ALENDRONATE 70MG TAB
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate 70mg once weekly
Study: 16626981
Drug: 1 mM
Normalized name: PhaSeal Protector, 21 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mM BMTd lotion applied twice daily for 14 days
Study: 16626981
Drug: 1 mM
Normalized name: PhaSeal Protector, 21 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mM BMTd lotion applied twice daily for 2 weeks to one eye
Study: 16626981
Drug: 2 mM
Normalized name: Adapta-Cap C 22 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mM BMTd lotion applied to lips
Study: 10997370
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (MA) 10 mg/kg/d
Study: 1327697
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus postoperative chemotherapy (SC)
Study: 1327697
Drug: Preoperative radiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiotherapy plus surgery followed by postoperative chemotherapy (RSC)
Study: 3906516
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine sulfate (MS)
Study: 30664397
Drug: Guided Physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided Physical Exercise and Dietary therapy (PED‐t)
Study: 27452293
Drug: Calcium hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium hydroxide medication
Study: 21951980
Drug: Psychosocial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial treatment (up to 6 months)
Study: 10102587
Drug: IAN block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAN block + intraosseous injection of 1.8 mL of 2% mepivacaine with 1:20,000 levonordefrin
Study: 10102587
Drug: IAN block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAN block + intraosseous injection of 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
Study: 10102587
Drug: IAN block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAN block + mock intraosseous injection
Study: 10102587
Drug: Heart rate
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart rate increase with intraosseous injection of mepivacaine and lidocaine
Study: 2116260
Drug: Pravastatin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin monotherapy (5 mg, 10 mg, and 20 mg twice daily)
Study: 2116260
Drug: Pravastatin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin with cholestyramine therapy
Study: 31638882
Drug: Group Music
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Music Therapy (GMT) combined with Treatment as Usual (TAU)
Study: 28625255
Drug: D3 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: D3 treatment group (supplemented 300 kU vitamin D3)
Study: 28625255
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (injected 1 mL physiological saline)
Study: 28625255
Drug: D3 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: D3 treatment group
Study: 27352341
Drug: Continuous sedation
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous sedation therapy with midazolam
Study: 22013734
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet (120 mg of starch)
Study: 18036708
Drug: IMVAMUNE (MVA)
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMVAMUNE (MVA) vaccine administered at Study Days 0 and 28 by subcutaneous or intramuscular injection
Study: 18036708
Drug: IMVAMUNE (MVA)
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMVAMUNE (MVA) vaccine
Study: 15023585
Drug: Fluoxetine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine plus olanzapine (5-10 mg, mean 6.1 mg)
Study: 14714042
Drug: Etanercept (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (25 mg twice per week subcutaneously)
Study: 7880782
Drug: 0.006% latanoprost
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.006% latanoprost given twice daily
Study: 26062190
Drug: Auricular point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular point sticking before operation combined with paracetamol and dihydrocodeine tartrate tablets, and diosmin tablets.
Study: 26062190
Drug: Paracetamol and
Normalized name: Paracetamol and tramadol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol and dihydrocodeine tartrate tablets, and diosmin tablets.
Study: 21455007
Drug: Daily glycerin
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily glycerin suppository (250 mg for 24‐27(+6) weeks subgroup or 500 mg for 28‐31(+6) weeks subgroup) for 10 days from 24 hours of age
Study: 21455007
Drug: Daily glycerin
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily glycerin suppository
Study: 18507650
Drug: 8 g/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g/l GOS/FOS in a 9 : 1 ratio (IMMUNOFORTIS)
Study: 18507650
Drug: 8 g/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g/l maltodextrine (placebo)
Study: 17692729
Drug: Probiotic-prebiotic complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic-prebiotic complex treatment
Study: 17692729
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (2 weeks after crossover to treatment)
Study: 15051746
Drug: Ximelagatran +
Normalized name: XIMELAGATRAN
DrugBank: Ximelagatran (DB04898)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran + Alcohol (0.5 g/kg for women, 0.6 g/kg for men)
Study: 9924220
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine 5 mg ml‐1
Study: 9924220
Drug: Isobaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isobaric bupivacaine 5 mg ml‐1
Study: 7800402
Drug: Bupivacaine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (30 cc of 0.25% bupivacaine with 1:200,000 epinephrine)
Study: 7800402
Drug: Morphine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (2 mg in 28 cc normal saline, total volume 30 cc)
Study: 24963830
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy-based training intervention (ACTr)
Study: 15130916
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) (estrogen plus progestin)